← All stocks

Dianthus Therapeutics, Inc. /DE/

DNTH Scheduled selling only

CIK 0001690585 #1220 in the set updated 21 Sep 2026

Bought (1 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (1 mo)

$4.49M

$0.00 on a plan · $4.49M straight out of an exercise

Sold at will

$0.00

0 of 8 sales

Net

−$4.49M

$0.00 against sales at will

By person

9 insiders · 8 transactions

10.8×

Marino Garcia holds 10.8 times base salary in stock. $6.82M of shares against $630.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Marino Garcia last reported holding, valued at $104.39, the price Common Stock was last bought or sold at on the open market here, on 17 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Randhawa Simrat

EVP, Head of R&D

—

$2.46M (3) scheduled

−$2.46M

4,000

0.0072%

$417.56K

0.0%

CARR EDWARD

CHIEF ACCOUNTING OFFICER

—

$2.03M (5) scheduled

−$2.03M

0.0000%

$0.00

—

Garcia Marino

CEO AND PRESIDENT

—

65,292

0.1167%

$6.82M

—

Veness Adam M

SVP, General Counsel and Sec.

—

15,000

0.0268%

$1.57M

—

Fairmount Funds Management LLC entity

Director

—

0.0000%

$0.00

−100.0%

Read Simon

Director

—

0.0000%

$0.00

—

McGeorge Anne

Director

—

0.0000%

$0.00

—

Savitz Ryan

EVP, CFO & CBO

—

0.0000%

$0.00

—

Soteropoulos Paula

Director

—

0.0000%

$0.00

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

CARR EDWARD

17 Sep 2026

CHIEF ACCOUNTING OFFICER

Sold after exercise

700

$104.39

$73.07K

CARR EDWARD

17 Sep 2026

CHIEF ACCOUNTING OFFICER

Sold after exercise

1,100

$103.20

$113.52K

CARR EDWARD

17 Sep 2026

CHIEF ACCOUNTING OFFICER

Sold after exercise

3,501

$102.39

$358.47K

CARR EDWARD

17 Sep 2026

CHIEF ACCOUNTING OFFICER

Sold after exercise

6,771

$101.37

$686.38K

CARR EDWARD

17 Sep 2026

CHIEF ACCOUNTING OFFICER

Sold after exercise

7,928

$100.43

$796.21K

Randhawa Simrat

1 Sep 2026

EVP, Head of R&D

Sold after exercise

13,309

$106.74

$1.42M

Randhawa Simrat

1 Sep 2026

EVP, Head of R&D

Sold after exercise

7,215

$106.25

$766.59K

Randhawa Simrat

1 Sep 2026

EVP, Head of R&D

Sold after exercise

2,600

$105.19

$273.49K

What was left out

Form 4 filings counted 2

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 8

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 43,124

History held since 27 Jun 2018